Carnosine as an effective neuroprotector in brain pathology and potential neuromodulator in normal conditions.

Carnosine (b-alanyl-L-histidine) is an endogenous dipeptide widely distributed in excitable tissues, such as muscle and neural tissues-though in minor concentrations in the latter. Multiple benefits have been attributed to carnosine: direct and indirect antioxidant effect, antiglycating, metal-chelating, chaperone and pH-buffering activity. Thus, carnosine turns out to be a multipotent protector against oxidative damage. However, the role of carnosine in the brain remains unclear. The key aspects concerning carnosine in the brain reviewed are as follows: its concentration and bioavailability, mechanisms of action in neuronal and glial cells, beneficial effects in human studies. Recent literature data and the results of our own research are summarized here. This review covers studies of carnosine effects on both in vitro and in vivo models of cerebral damage, such as neurodegenerative disorders and ischemic injuries and the data on its physiological actions on neuronal signaling and cerebral functions. Besides its antioxidant and homeostatic properties, new potential roles of carnosine in the brain are discussed.

[Lipoilcarnosine: synthesis, study of physico-chemical and antioxidant properties, biological activity]. / Lipoilkarnozin: sintez, izuchenie fiziko-khimicheskikh i antioksidantnykh svoistv, biologicheskaia aktivnost'.

Synthesis of lipoilcarnosine (LipC) - a conjugated molecule based on two natural antioxidants, carnosine and a-lipoic acid, is described. Its physico-chemical, antioxidant properties and biological activity are characterized. According to reversed-phase HPLC with a UV detector, purity of the final product was 89.3%. The individuality of the obtained sodium salt of LipC was confirmed by tandem HPLC-mass spectrometry. High resistance of LipC to hydrolysis with serum carnosinase was demonstrated. The antioxidant activity of LipC measured by reaction with the formation of thiobarbituric acid reacting substances and kinetic parameters of iron-induced chemiluminescence was higher than that of carnosine and lipoic acid. LipC did not affect viability of SH-SY5Y human neuroblastoma culture cells, differentiated towards the dopaminergic type, at concentrations not exceeding 5 mM. At the concentration range of 0.1-0.25 mM LipC protected neuronal cells against 1-methyl-4-phenylpyridinium (MPP + )-induced toxicity.

[The clinical significance of the lamotrigine pharmacokinetic variability]. / Klinicheskoe znachenie farmakokineticheskoi variabel'nosti lamotridzhina.

AIM: To estimate pharmacokinetic variability of lamotrigine (LTG) and its clinical significance. MATERIAL AND METHODS: One hundred patients, including 74 women, aged from 18 to 77 years (38.23±14.37 years), with focal epilepsy were examined. Monotherapy with LTG was administered to 54 patients, duotherapy to 46 patients (LTG and valproic acid combination to 27 patients, LTG and liver enzymes inducers to 19 patients). Patients underwent procedures of therapeutic drug monitoring (TDM). Minimal (Cssmin) and maximal (Cssmax) steady-state LTG plasma concentrations, and concentration-to-weight ratio (CDR) were calculated. RESULTS AND CONCLUSION: In patients who used LTG in monotherapy, LTG Cssmin was 5.6±4.65 mg/l, Cssmax 7.59±5.54 mg/l. In the group that received LTG in combination with valproate, LTG Сssmin was 7.8 [5.4; 11.8] mg / l and Cssmax 11.4 [7.3; 15.3] mg/l. In the group that received LTG in combination with drug-inducers of glucuronidation, Cssmin was 2.5 [1.99; 4.32] mg/l, Cssmax 4.73 [2.91; 6.70] mg/l. Statistically significant differences in CDR parameter between groups with LTG monotherapy and duotherapy, both with inducer and with inhibitors, as well as between groups of duotherapy with inductors and with inhibitors were obtained. The results of the study indicate a pronounced pharmacokinetic variability of the LTG. Conducting TDM allows the establishment of individual therapeutic concentrations of LTG in blood plasma and setting a correction vector for antiepileptic therapy.

Neuroprotective Effect of Carnosine on Primary Culture of Rat Cerebellar Cells under Oxidative Stress.

Dipeptide carnosine (ß-alanyl-L-histidine) is a natural antioxidant, but its protective effect under oxidative stress induced by neurotoxins is studied insufficiently. In this work, we show the neuroprotective effect of carnosine in primary cultures of rat cerebellar cells under oxidative stress induced by 1 mM 2,2'-azobis(2-amidinopropane)dihydrochloride (AAPH), which directly generates free radicals both in the medium and in the cells, and 20 nM rotenone, which increases the amount of intracellular reactive oxygen species (ROS). In both models, adding 2 mM carnosine to the incubation medium decreased cell death calculated using fluorescence microscopy and enhanced cell viability estimated by the MTT assay. The antioxidant effect of carnosine inside cultured cells was demonstrated using the fluorescence probe dichlorofluorescein. Carnosine reduced by half the increase in the number of ROS in neurons induced by 20 nM rotenone. Using iron-induced chemiluminescence, we showed that preincubation of primary neuronal cultures with 2 mM carnosine prevents the decrease in endogenous antioxidant potential of cells induced by 1 mM AAPH and 20 nM rotenone. Using liquid chromatography-mass spectrometry, we showed that a 10-min incubation of neuronal cultures with 2 mM carnosine leads to a 14.5-fold increase in carnosine content in cell lysates. Thus, carnosine is able to penetrate neurons and exerts an antioxidant effect. Western blot analysis revealed the presence of the peptide transporter PEPT2 in rat cerebellar cells, which suggests the possibility of carnosine transport into the cells. At the same time, Western blot analysis showed no carnosine-induced changes in the level of apoptosis regulating proteins of the Bcl-2 family and in the phosphorylation of MAP kinases, which suggests that carnosine could have minimal or no side effects on proliferation and apoptosis control systems in normal cells.

[Experimental study of the basic pharmacokinetic characteristics of dipeptide carnosine and its efficiency of penetration into brain tissues].

We have used an original chromatography/mass spectrometry technique to study the pharmacokinetics of dipeptide carnosine in C57 Black/6 mice after intra-peritoneal administration of the drug at a dose of 1 g/kg. The basic pharmacokinetic characteristics of carnosine were measured the in the blood and brain. The obtained concentration-time curve has a biexponential character. It is shown that the maximum concentration of carnosine in the blood plasma is Cmax = 1081.75 ± 124.24 µg/mL and it is achieved in a time interval of Tmax = 0.25 h. We showed that i.p. administration of exogenous carnosine could significantly increase the concentration of that substance in the brain. Tissue availability of dipeptide carnosine for brain tissue is relatively good and constitutes 59% from the total amount of blood carnosine. It was found that the maximum concentration of carnosine in the brain occurs at the sixth hour after i.p. administration when the concentration of drug in the blood is minimal.

[Experimental study of pinostrobine oxime biotransformation].

We have experimentally studied pathways of elimination of an oximized derivative of phytoflavonoid pinostrobine by HPLC/mass spectrometry. Four potential metabolites of pinostrobine oxime have been found and there was an attempt to determine their molecular structures on the basis of their fragmentation under positive electrospray ionization conditions. It is established that pinostrobine oxime is removed from the organism mainly unchanged and also in the form of glucuronated derivative.

[Pantogam and pantogam active: qualitative and quantitative features of the interaction with neurotransmitter receptors in vitro].

We conducted a comparative study on the effect of active compounds of pantogam and pantogam active (calcium D(R)-homopantothenate and calcium DL(RS)-homopantothenate) and its L(S)-isomer on the receptors of main brain neuromediators in rats using in vitro radioligand binding analysis. All three compounds interact with binding sites of specific GABA-A and, in particular, GABA-B receptor ligands. Racemate and S-enantiomer, but not its R-form, competed to a moderate degree for D2-receptor binding sites. In all cases, degrees of interaction with receptors were ranged as follows: S-isomer>racemate>R-isomer. These qualitative and quantitative differences are assumed to contribute to pharmacological activity of both drugs.

Binding of specific ligand by D2- and NMDA-receptors of striatum cells in two rat strains predisposed and resistant to audiogenic seizures.

We studied parameters of specific receptor binding of D2-dopamine receptor ligand [(3)H]-sulpiride and NMDA-receptor ligand [(3)H]-MK-801 on the membranes of striatum cells in Krushinsky-Molodkina rats (predisposed to audiogenic seizures) and strain "0" selected for the absence of audiogenic seizures. No interstrain differences were observed in affinity (K(d)) of both D2- and NMDA-receptors to ligands. At the same time, significant interstrain differences in receptor density (B(max)) were found for both D2-receptors and NMDA-receptors. The reduced number of dopamine and glutamate receptors in the striatum can be associated with neurological peculiarities of Krushinsky-Molodkina rat strain (audiogenic seizures and postictal catalepsy).

[Role of the brain dopaminergic and serotoninergic systems in psychopharmacological effects of ladasten and sydnocarb].

The influence of ladasten and sydnocarb on dopamine and serotonin receptors and the biosynthesis and re-uptake of dopamine and serotonin has been studied. It is established that both drugs do not produce any direct effects on dopamine D1, D2, and D3 receptors in rat striatum as well as on serotonin 5-HT1A and 5-HT2A receptors in rat frontal cortex in vitro. Ladasten in a single dose of 50 mg/kg (i.p.) stimulated ex vivo dopamine biosynthesis and release in striatum, without any influence on serotonin formation neither in striatum nor in frontal cortex. On the contrary, sydnocarb (17.5 mg/kg, i.p.) decreased the level of serotonin synthesis both in striatum and frontal cortex, while not affecting the biosynthesis of dopamine. Both ladasten and sydnocarb inhibited the active transport of dopamine in rat striatal synaptosomes at IC50 = 3.56 microM and 28.66 nM, respectively, but failed to influence the serotonin re-uptake in rat frontal cortex.

[Drug bioavailability improvement by means of nanopharmacology: pharmacokinetics of liposomal drugs].

Modern approaches to increasing the efficiency of liposomal transport of substances are discussed. Examples of creating new nanopharmacological drugs that exceed the pharmacokinetic characteristic of their classical analogs are given.

[Ligands of glutamate and dopamine receptors evenly labeled with hydrogen isotopes].

A reaction of high-temperature solid-phase catalytic isotope exchange (HSCIE) was studied for the preparation of tritium- and deuterium-labeled ligands of glutamate and dopamine receptors. Tritium-labeled (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclopenten-5,10-imine ([G-(3)H]MK-801) and R(+)-7-hydroxy-N,N-di-n-propyl-2-aminotetraline ([G-(3)H]-7-OH-DPAT) were obtained with a specific activity of 210 and 120 Ci/mol, respectively. The isotopomeric distribution of deuterium-labeled ligands was studied using time-of-flight mass-spectrometer MX 5310 (ESI-o-TOF) with electrospray and orthogonal ion injection. Mean deuterium incorporation per ligand molecule was 11.09 and 3.21 atoms for [G-(2)H]MK-801 and [G-(2)H]-7-OH-DPAT, respectively. The isotope label was shown to be distributed all over the ligand molecule. The radioreceptor binding of tritium-labeled ligands [G-(3)H]MK-801 and [G-(3)H]-7-OH-DPAT was analyzed using the brain structure of Vistar rats. It was demonstrated that [G-(3)H]MK-801 specifically binds to hippocampus membranes with K(d) 8.3 +/- 1.4 nM, B(max) being 3345 +/- 300 fmol/mg protein. The [G-(3)H]-7-OH-DPAT ligand specifically binds to rat striatum membranes with K(d) 10.01 +/- 0.91 nM and B(max) 125 +/- 4.5 fmol/mg protein. It was concluded that the HSCIE reaction can be used for the preparation of highly tritium-labeled (+)-MK-801 and 7-OH-DPAT with retention of their physiological activities.

[Effects of antiparkinsonian drug hemantane on the level and metabolism of biogenic monoamines in brain structures of C57BL/6 mice].

Hemantane (N-adamant-2-yl-hexamethyleneimine hydrochlortide) is a new antiparkinsonian drug showing a broad activity spectrum, being superior to the reference drug amantadine in some tests. The effects of hemantane on the levels of biogenic amines and their metabolites in the striatum, frontal cortex, and hippocampus have been studied in C57BL/6 mice. It was found that a single administration of hemantane (20 mg/kg, i.p.) decreased the concentration of DOPA, serotonin, and its metabolite in mice striatum, gently inhibited the synthesis of dopamine in mice striatum, and influenced the HVA/DA balance in frontal cortex homogenates.

Effect of antiparkinsonian drug himantane on the content of dopamine transporter DAT protein in rat striatum and cultured pheochromocytoma PC-12 cells.

We studied the effects of antiparkinsonian drug himantane (acute and subchronic administration) on the content of dopamine transporter protein DAT in rat striatum ex vivo and on the content of DTA in cultured PC-12 cells (10(-5) - 10(-7) M, the preparation was added to the incubation medium once or 7 times). The preparation significantly reduced the content of DAT protein both ex vivo and in vitro.

[Effects of hemantane on the main subtypes of dopamine receptors in the rat striatum ex vivo].

The effect of the antiparkinsonian drug hemantane on various subtypes of dopamine receptors in the striatum of Wistar rats have been studied after subchronic administration of the drug in a single daily dose of 20 mg/kg (i.p.) over seven days. The receptor binding was studied using the striatum membranes isolated from the test rats decapitated after the last injection of the drug. A modulatory influence of hemantane on the D1, D2 and D3 type receptors was revealed. It was found that hemantane increased the density of the binding sites of D1 receptors and decreased the density of the binding sites of D2 and D3 receptors without changing their affinity to the selective ligands. These results indicate that the subchronic administration ofhemantane can lead to the functional rearrangement of the main subtypes of dopamine receptors in the rat striatum.

[The acute and subchronic effects of hemantane on [3H]-dopamine reuptake in rat striatal synaptosomes ex vivo].

The ex vivo effects of the new antiparkinsonian drug (adamantane derivative) hemantane on the [3H]-dopamine reuptake rate (V) in striatum have been studied upon acute and subchronic administration of the drug in Wistar rats. The [3H]-dopamine reuptake was measured in striatal synaptosomes isolated from rats decapitated 1 hour after drug injection (40 mg/kg, i.p.), and in synaptosomes of rats treated for 7 days with hemantane (single daily dose, 20 mg/kg, i.p.). The acute experiment resulted in a significant (30%) decrease in the apparent Vmax of [3H]-dopamine reuptake, while the value of the apparent Km remained unchanged. The data obtained indicate that hemantane suppresses the DA transporter function within physiological concentration range via noncompetitive mode. In contrast, subchronic drug administration increases by 17% the apparent Vmax. These results demonstrate the active participation of presynaptic transport mechanism in dopamine-positive effects of hemantane.